Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular use

Current effective version

PDF iconRevision 1 - Adopted guideline

Reference numberCPMP/BPWG/143744/2011 Rev. 1
Published26/03/2015
Effective from01/09/2015
KeywordsHuman normal immunoglobulin, primary immunodeficiency syndromes, hypogammaglobulinaemia, hepatitis A prophylaxis, immunomodulation
DescriptionThis document describes the information to be included in the summary of product characteristics for human normal immunoglobulins for subcutaneous and/or intramuscular administration.


Document history

Revision 1

Current version

PDF iconAdopted guideline


PDF iconOverview of comments


PDF iconDraft guideline


PDF iconConcept paper

In operation: 01/09/2015–present


Published: 26/03/2015


Published: 31/07/2012


Published: 17/12/2010

First version PDF iconAdopted guideline In operation: 01/01/2003–31/08/2015


Related content


How useful was this page?

Add your rating
Average
1 rating